ArticleFrontiers in immunology2025
Aberrant expression of PYGB as a potential therapeutic target and its associations with immune cell infiltration in lung cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Brain glycogen phosphorylase (PYGB) facilitates the breakdown of glycogen, thereby supplying energy to tumor cells. While PYGB expression has been documented in various tumor types, its specific function in lung cancer (LC) remains to be elucidated. This study aims to explore the potential involvement of PYGB in the initiation and progression of LC. Methods and results: We systematically analyzed PYGB in LC using data from the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) Cancer database, employing R and various online analytical tools. Elevated PYGB expression was observed in LC and was associated with poor clinical outcomes. Conclusions: This study unveils that elevated PYGB expression in LC is significantly correlated with poor prognosis, potentially attributable to PYGB's facilitation of LC cell proliferation, migration, and metastasis, as well as its significant association with the immune microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.